[1]王志美,徐忠伟,王佳宝,等.蟾酥活性成分协调索拉非尼通过下调Akt/NF-κB信号途径抑制肝癌HepG2细胞生长[J].中国药理学通报,2017,(11):1510-1516.[doi:10.3969/j.issn.1001-1978.2017.11.008]
 WANG Zhi-mei,XU Zhong-wei,WANG Jia-bao,et al.Synergy with the active ingredients of toad venom and sorafenib suppresses hepatocellular carcinoma HepG2 cells proliferation through down-regulating Akt/NF-κB signaling pathways[J].Chinese Pharmacological Bulletin,2017,(11):1510-1516.[doi:10.3969/j.issn.1001-1978.2017.11.008]
点击复制

蟾酥活性成分协调索拉非尼通过下调Akt/NF-κB信号途径抑制肝癌HepG2细胞生长()
分享到:

《中国药理学通报》[ISSN:/CN:]

卷:
期数:
2017年11期
页码:
1510-1516
栏目:
论著
出版日期:
2017-10-20

文章信息/Info

Title:
Synergy with the active ingredients of toad venom and sorafenib suppresses hepatocellular carcinoma HepG2 cells proliferation through down-regulating Akt/NF-κB signaling pathways
文章编号:
1001-1978(2017)11-1510-07
作者:
王志美1徐忠伟2王佳宝1代二庆3徐瑞成24
1.锦州医科大学中国人民武装警察部队后勤学院附属医院研究生培养基地,天津 300162;
2.中国人民武装警察部队后勤学院中心实验室,天津 300162;
3.中国人民武装警察部队后勤学院附属医院军人医疗保健中心,天津 300162;
4.天津市职业与环境危害生物标志物重点实验室,天津 300309
Author(s):
WANG Zhi-mei1 XU Zhong-wei2 WANG Jia-bao1 DAI Er-qing3 XU Rui-cheng24
1.the Postgraduate Culture Base of Jinzhou Medical University-the Affiliated Hospital of Logistics University of Chinese People's Armed Police Force, Tianjin 300162, China;
2.Central Laboratory Logistics University of Chinese People's Armed Police Force,Tianjin 300162, China;
3.the Affiliated Hospital of Logistics University of Chinese People's Armed Police Force, Tianjin 300162, China;
4.Key Lab for Biomarkers of Occupational and Environmental Hazard, Tianjin 300309, China
关键词:
索拉非尼 蟾酥 蟾蜍灵 华蟾毒配基 HepG2 Akt NF-κB
Keywords:
sorafenib toad venom bufalin cinobufagin HepG2 Akt NF-κB
分类号:
R282.74;R329.24;R329.28;R735.7;R979.1
DOI:
10.3969/j.issn.1001-1978.2017.11.008
文献标志码:
A
摘要:
目的 探讨蟾酥活性成分蟾蜍灵和华蟾毒配基协调索拉非尼抑制肝癌HepG2细胞生长的机制。方法 MTT法检测HepG2细胞经药物作用12、24、48 h后的增殖活性; Hoechst 33342荧光染色检测细胞形态学变化; 流式细胞仪检测药物对HepG2细胞周期的影响; Western blot检测Akt、p-Akt(Ser473)、IκB、NF-κB、p-NF-κB p65、Bcl-2、Bax、cyclin A、PCNA蛋白表达水平。结果 蟾蜍灵、华蟾毒配基和索拉非尼作用组均能抑制HepG2细胞增殖,且药物联合作用组的增殖抑制率明显高于单独药物作用组,呈时间依赖性,用金氏公式得出在24 h具有协同作用(P<0.01); 荧光染色结果显示,HepG2细胞经药物处理24 h后,细胞呈现出核染色质凝集的凋亡形态特征; 细胞周期检测结果显示,索拉非尼作用组使细胞周期阻滞于G0/G1期(P<0.01),蟾蜍灵、华蟾毒配基作用组使细胞周期阻滞于S期(P<0.01),药物联合作用组使细胞周期阻滞于S期(P<0.01); Western blot结果显示,蟾蜍灵、华蟾毒配基和索拉非尼单独药物作用组和联合作用组Akt、NF-κB总蛋白表达均无明显变化,p-Akt(Ser473)、p-NF-κB p65、Bcl-2、cyclin A、PCNA蛋白表达水平逐渐降低,联合作用组比单独药物作用组降低更为明显(P<0.01)。IκB、Bax蛋白表达水平逐渐升高,联合作用组比单独药物作用组升高更加明显(P<0.01)。结论 蟾酥活性成分蟾蜍灵和华蟾毒配基协调索拉非尼通过下调Akt/NF-κB信号通路,抑制肝癌HepG2细胞增殖。
Abstract:
Aim To investigate the effect of the active ingredients of toad venom(bufalin and cinobufagin)combined with sorafenib on the growth of hepatocellular carcinoma HepG2 cells, and to explore the possible mechanism. Methods The rates of inhibition after treated with drugs 12, 24, 48 h were detected by MTT assay. The changes of cell morphology were detected by Hoechst 33342 fluorescent staining. The changes of cell cycle were detected by flow cytometry. The expressions of proteins such as Akt, p-Akt(Ser473), IκB, NF-κB, p-NF-κB p65, Bcl-2, Bax, cyclin A, PCNA were detected by Western blot. Results Bufalin, cinobufagin and sorafenib could inhibit the proliferation of HepG2 cells, presenting a dose- and time-dependent manner. Meanwhile, it could significantly increase the inhibitory rate of cells compared with those of single treatment, and they performed a synergistic activity in sorafenib combined with cinobufagin or bufalin by Jin Formula after 24 h treatment(P<0.01). The results of fluorescence staining showed the observation of the morphological features of nuclear condensation. Sorafenib induced the cell cycle G0/G1 phase arrest(P<0.01), and bufalin, cinobufagin and the combination treatment generated the cell cycle S phase arrest(P<0.01). The results of Western blot showed that the expressions of Akt, NF-κB were not obviously changed between control and all other treatment. The expression levels of p-Akt(Ser473), p-NF-κB p65, Bcl-2, PCNA and cyclin A in combination treatment significantly decreased, and the expression levels of IκB and Bax significantly increased compared to those in single treatment(P<0.01). Conclusion The active ingredients of toad venom(bufalin and cinobufagin)combined with sorafenib performs a synergetic effect on the anti-cancer of HepG2 cells by down-regulating Akt/NF-κB signaling pathway.

参考文献/References:

[1] 夏丽洁, 张富春. 肝癌治疗新靶点GPC3研究进展[J]. 中国药理学通报, 2016, 32(11):1486-9.
[1] Xia L J,Zhang F C. Advances in GPC3 research on new target of liver cancer [J]. Chin Pharmacol Bull, 2016, 32(11):1486-9.
[2] Zhu Y J, Zheng B, Wang H Y, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer[J]. Acta Pharmacol Sin, 2017, 38(5):614-22.
[3] Xu Z W, Wang F M, Fan F X, et al. Quantitative proteomics reveals that the inhibition of Na(+)/K(+)-ATPase activity affects S-phase progression leading to a chromosome segregation disorder by attenuating the Aurora A function in hepatocellular carcinoma cells[J]. J Proteome Res, 2015, 14(11): 4594-602.
[4] Zhen S, Hua L, Liu Y H, et al. Bufalin attenuates the proliferation of breast cancer MCF-7 cells in vitro and in vivo by inhibiting the PI3K/Akt pathway[J]. Int J Clin Exp Med, 2016, 9(6): 10297-303.
[5] Zhang G, Wang C, Sun M, et al. Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells[J]. Oncotarget, 2016, 7(20): 28935-46.
[6] Li M, Yu X, Guo H, et al. Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells[J]. Tumour Biol, 2014, 35(3):2461-71.
[7] Yin J Q, Wen L, Wu L C, et al. The glycogen synthase kinase-3β/nuclear factor-kappa B pathway is involved in cinobufagin-induced apoptosis in cultured osteosarcoma cells[J]. Toxicol Lett, 2013, 218(2):129-36.
[8] 徐忠伟, 王凤梅, 王聪聪,等.钠钾ATP酶抑制剂通过调节DNA损伤感应复合体Mre11/Rad50/Nbs1的表达诱导肝癌HepG2细胞周期阻滞[J]. 中国药理学通报, 2016, 32(3): 323-7.
[8] Xu Z W,Wang F M,Wang C C,et al. Na+,K+-ATPase inhibitor induces cell cycle arrest in liver cancer HepG2 cells by regulating expression of DNA damage Mre11/Rad50/Nbs1 complex[J]. Chin Pharmacol Bull, 2016, 32(3):323-7
[9] Sokolowski K M, Koprowski S, Kunnimalaiyaan S, et al. Potential molecular targeted therapeutics: role of PI3K/Akt/mTOR inhibition in cancer[J]. Anticancer Agents Med Chem, 2016, 16(1):29-37.
[10] Zhang C Z, Wang X D, Wang H W, et al. Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression[J]. J BUON, 2015, 20(1):218-22.
[11] Gedaly R, Angulo P, Chen C, et al. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment[J]. Anticancer Res, 2012, 32(7): 2531-6.
[12] Li J, Wang S, Su Z F, Yuan Y.Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations [J]. Contemp Oncol(Pozn), 2016, 20(1):33-8.
[13] Jiang S S, Wang Q, Feng M Q, et al.C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/Akt/mTOR and ERK signaling pathways in HCC cells [J]. Appl Microbiol Biotechnol, 2017, 101(4):1535-46.
[14] Huang H, Li L J, Zhang H B, Wei A Y. Papaverine selectively inhibits human prostate cancer cell(PC-3)growth by inducing mitochondrial mediated apoptosis, cell cycle arrest and downregulation of NF-κB/PI3K/Akt signalling pathway [J]. J BUON,2017,22(7):112-8.
[15] Wang S, Liu Z, Wang L, Zhang X. NF-κB signaling pathway, inflammation and colorectal cancer[J]. Cell Mol Immunol, 2009, 6(5):327-34.
[16] Ke F, Wang Z, Song X, et al. Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NF-κB pathways in cholangiocarcinoma cells. [J]. Drug Des Devel Ther, 2017,11:1753-66.

相似文献/References:

[1]王芳,符立梧.多靶点抗肿瘤新药索拉非尼的研究进展[J].中国药理学通报,2008,(08):0.
 WANG Fang,FU Li wu.Research advances in sorafenib: a multiple targeted antitumor agent[J].Chinese Pharmacological Bulletin,2008,(11):0.
[2]朱云,程旸,李爱民.原发性肝细胞癌对索拉非尼耐药机制的研究进展[J].中国药理学通报,2013,(06):752.
 ZHU Yun,CHENG Yang,LI Ai min.Mechanisms of drug resistance to sorafenib in hepatocellular carcinoma[J].Chinese Pharmacological Bulletin,2013,(11):752.
[3]李静,潘跃银,张颖.索拉非尼联合吉西他滨对k-ras基因突变肺癌细胞株的增殖抑制作用及其机制[J].中国药理学通报,2014,(03):421.
 LI Jing,PAN Yue-yin,ZHANG Ying.Inhibitory effect of sorafenib combined with gemcitabine on human none-small cell lung cancer cells harboring k-ras gene mutation and its mechanism[J].Chinese Pharmacological Bulletin,2014,(11):421.

备注/Memo

备注/Memo:
收稿日期:2017-08-19,修回日期:2017-09-21
基金项目:国家自然科学基金资助项目(No 81673651,81273552,81273745); 武警后勤学院博士启动金项目(No WHB201501)
作者简介:王志美(1989-),女,硕士生,研究方向:中西医结合临床,E-mail:1032924476@qq.com;
代二庆(1969-),男,博士,教授,硕士生导师,研究方向:中西医结合临床,通讯作者,E-mail:13502136445@163.com;
徐瑞成(1968-),男,硕士,教授,硕士生导师,研究方向:细胞信号转导,通讯作者,Tel:022-84876451,E-mail:xu_rc@sohu.com
更新日期/Last Update: 2017-10-20